Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 10, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:
- Chardan Inaugural Gene Therapy Conference, October 10, 2017, New York, and
- Jefferies Gene Technology Summit, October 12, 2017, New York.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200
Email: [email protected]
Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200
Email: [email protected]
Media
David Schull
Russo Partners
Phone: 858-717-2310
Email: [email protected]
